Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside ( 131I-IAZGP) digital autoradiography

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 2, 2010, Pages 339-348

  Li, Xiao Feng ^a,b,d   Sun, Xiaorong ^a,c   Ma, Yuanyuan ^a   Suehiro, Makiko ^a   Zhang, Mutian ^a   Russell, James ^a   Humm, John L ^a   Ling, C Clifton ^a   O'Donoghue, Joseph A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^d University of Louisville School of Medicine   (United States)

Author keywords

Autoradiography; Hypoxia radiotracer; Iodo azomycin galactopyranoside; Micrometastasis; Tumor hypoxia

Indexed keywords

CARBONATE DEHYDRATASE IX; IODOAZOMYCIN GALACTOPYRANOSIDE IODINE 131; PIMONIDAZOLE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PERITONEAL DISEASE; TUMOR VOLUME;

ANIMALS; ANTIGENS, NEOPLASM; AUTORADIOGRAPHY; BIOLOGICAL TRANSPORT; CARBONIC ANHYDRASES; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; GALACTOSIDES; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASMS; NITROIMIDAZOLES; RADIOACTIVE TRACERS; RADIOGRAPHIC IMAGE ENHANCEMENT;

EID: 77949264237     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1310-y     Document Type: Article

References (40)

1. XF Li S Carlin M Urano J Russell CC Ling JA O'Donoghue 2007 Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy Cancer Res 67 7646 7653 10.1158/0008-5472.CAN-06-4353 1:CAS:528:DC%2BD2sXptVGlsLg%3D 17699769 (Pubitemid 47281357)
2. XF Li JA O'Donoghue 2008 Hypoxia in microscopic tumors Cancer Lett 264 172 180 10.1016/j.canlet.2008.02.037 1:CAS:528:DC%2BD1cXlslSisb8%3D 18384940
3. L Bentzen S Keiding MR Horsman L Falborg SB Hansen J Overgaard 2000 Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography-a study evaluating [18F]fluoro-2-deoxy-D-glucose Acta Oncol 39 629 637 10.1080/028418600750013320 1:STN:280:DC%2BD3M%2Fkt12ltg%3D%3D 11093372
4. L Dubois W Landuyt K Haustermans P Dupont G Bormans P Vermaelen, et al. 2004 Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry Br J Cancer 91 1947 1954 10.1038/sj.bjc.6602219 1:STN:280:DC%2BD2croslyitQ%3D%3D 15520822 (Pubitemid 40065524)
5. F He X Deng B Wen Y Liu X Sun L Xing, et al. 2008 Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers Cancer Res 68 8597 8606 10.1158/0008-5472.CAN-08-0677 1:CAS:528:DC%2BD1cXht1CmsbjP 18922936
6. AL Vāvere JS Lewis 2007 Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia Dalton Trans 43 4893 4902 10.1039/b705989b 17992274 (Pubitemid 350015414)
7. JL Tatum GJ Kelloff RJ Gillies JM Arbeit JM Brown KS Chao, et al. 2006 Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy Int J Radiat Biol 82 699 757 10.1080/09553000601002324 1:CAS:528:DC%2BD28XhtlejsbnM 17118889 (Pubitemid 44832019)
8. JA O'Donoghue P Zanzonico A Pugachev B Wen P Smith-Jones S Cai, et al. 2005 Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models Int J Radiat Oncol Biol Phys 61 1493 1502 15817355
9. RV Iyer EL Engelhardt CC Stobbe RF Schneider JD Chapman 1998 Preclinical assessment of hypoxic marker specificity and sensitivity Int J Radiat Oncol Biol Phys 42 741 745 1:CAS:528:DyaK1MXlvVKn 9845088
10. P Zanzonico J O'Donoghue JD Chapman R Schneider S Cai S Larson, et al. 2004 Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning Eur J Nucl Med Mol Imaging 31 117 128 10.1007/s00259-003-1322-y 14523586 (Pubitemid 38133549)
11. CC Riedl P Brader PB Zanzonico YS Chun Y Woo P Singh, et al. 2008 Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET Radiology 248 561 570 10.1148/radiol.2482071421 18641253
12. AS Ljungkvist J Bussink JH Kaanders AJ van der Kogel 2007 Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers Radiat Res 167 127 145 10.1667/RR0719.1 1:CAS:528:DC%2BD2sXhtlOhs78%3D 17390721 (Pubitemid 46214661)
13. X Sun XF Li J Russell L Xing M Urano GC Li, et al. 2008 Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry Radiother Oncol 88 269 276 10.1016/j.radonc.2008.05.015 18538874
14. JH Kaanders KI Wijffels HA Marres AS Ljungkvist LA Pop FJ van den Hoogen, et al. 2002 Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer Cancer Res 62 7066 7074 1:CAS:528: DC%2BD38XpsVahtro%3D 12460928
15. JA Raleigh DP Calkins-Adams LH Rinker CA Ballenger MC Weissler WC Fowler Jr, et al. 1998 Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker Cancer Res 58 3765 3768 1:CAS:528:DyaK1cXlvVyrtbY%3D 9731480
16. JA Raleigh SC Chou GE Arteel MR Horsman 1999 Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors Radiat Res 151 580 589 10.2307/3580034 1:CAS:528: DyaK1MXjtVamur8%3D 10319731 (Pubitemid 29381608)
17. AS Ljungkvist J Bussink PF Rijken JA Raleigh J Denekamp AJ Van Der Kogel 2000 Changes in tumor hypoxia measured with a double hypoxic marker technique Int J Radiat Oncol Biol Phys 48 1529 1538 1:STN:280:DC%2BD3M%2FnvVWhtQ%3D%3D 11121659
18. A Driessen W Landuyt S Pastorekova J Moons L Goethals K Haustermans, et al. 2006 Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas Ann Surg 243 334 340 10.1097/01.sla.0000201452.09591.f3 16495697 (Pubitemid 43327764)
19. PJ Hoskin A Sibtain FM Daley GD Wilson 2003 GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON Br J Cancer 89 1290 1297 10.1038/sj.bjc.6601260 1:CAS:528:DC%2BD3sXns1Cmu7w%3D 14520462 (Pubitemid 37363419)
20. CP Potter AL Harris 2003 Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer Br J Cancer 89 2 7 10.1038/sj.bjc.6600936 1:CAS:528:DC%2BD3sXltVWms7k%3D 12838292 (Pubitemid 36897927)
21. MI Koukourakis A Giatromanolaki E Sivridis K Simopoulos J Pastorek CC Wykoff, et al. 2001 Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy Clin Cancer Res 7 3399 3403 1:CAS:528:DC%2BD3MXptFaisr8%3D 11705854
22. AL Harris 2002 Hypoxia-a key regulatory factor in tumour growth Nat Rev Cancer 2 38 47 10.1038/nrc704 1:CAS:528:DC%2BD38XhvF2jtL4%3D 11902584
23. S Sobhanifar C Aquino-Parsons EJ Stanbridge P Olive 2005 Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors Cancer Res 65 7259 7266 10.1158/0008-5472.CAN-04-4480 1:CAS:528:DC%2BD2MXns1Wrurs%3D 16103077 (Pubitemid 41161257)
24. EG Troost J Bussink JH Kaanders J van Eerd JP Peters PF Rijken, et al. 2005 Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines Radiother Oncol 76 194 199 10.1016/j.radonc.2005.06.031 1:CAS:528:DC%2BD2MXpslChsbk%3D 16024110 (Pubitemid 41725447)
25. KH Shin JA Diaz-Gonzalez J Russell Q Chen P Burgman XF Li, et al. 2007 Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole Cancer Biol Ther 6 70 75 10.1158/1535-7163.MCT-06-0125 1:CAS:528: DC%2BD2sXhtVeqsb7I 17172824 (Pubitemid 46206669)
26. A Pugachev S Ruan S Carlin SM Larson J Campa CC Ling, et al. 2005 Dependence of FDG uptake on tumor microenvironment Int J Radiat Oncol Biol Phys 62 545 553 1:CAS:528:DC%2BD2MXktFGhsLg%3D 15890599
27. RF Schneider EL Engelhardt CC Stobbe MC Fenning JD Chapman 1997 The synthesis and radiolabelling of novel markers of tissue hypoxia of the iodinated azomycin nucleoside class J Labelled Compd Radiopharm 39 541 557 10.1002/(SICI)1099-1344(199707)39:7<541::AID-JLCR5>3.0.CO;2-B 1:CAS:528:DyaK2sXksFCqsL8%3D (Pubitemid 27270514)
28. M Suehiro P Burgman S Carlin S Burke GB Yang O Ouerfelli, et al. 2009 Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker-is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker? Nucl Med Biol 36 477 487 10.1016/j.nucmedbio.2009.03.002 1:CAS:528:DC%2BD1MXnt1Gqtrk%3D 19520288
29. JM Brown WR Wilson 2004 Exploiting tumour hypoxia in cancer treatment Nat Rev Cancer 4 437 447 10.1038/nrc1367 1:CAS:528:DC%2BD2cXksVaisbs%3D 15170446
30. G Melillo 2007 Targeting hypoxia cell signaling for cancer therapy Cancer Metastasis Rev 26 341 352 10.1007/s10555-007-9059-x 1:CAS:528: DC%2BD2sXotFWrtb4%3D 17415529
31. WA Denny WR Wilson 2000 Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia Expert Opin Investig Drugs 9 2889 2901 10.1517/13543784.9.12.2889 1:CAS:528:DC%2BD3cXosFKqu7w%3D 11093359
32. J von Pawel R von Roemeling U Gatzemeier M Boyer LO Elisson P Clark, et al. 2000 Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors J Clin Oncol 18 1351 1359
33. D Rischin RJ Hicks R Fisher D Binns J Corry S Porceddu, et al. 2006 Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2098 2104 10.1200/JCO.2005.05.2878 16648512 (Pubitemid 46622121)
34. SB Reddy SK Williamson 2009 Tirapazamine: a novel agent targeting hypoxic tumor cells Expert Opin Investig Drugs 18 77 87 10.1517/13543780802567250 1:CAS:528:DC%2BD1cXhsVGhtbrF 19053884
35. AS Lalani SE Alters A Wong MR Albertella JL Cleland WD Henner 2007 Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer Clin Cancer Res 13 2216 2225 10.1158/1078-0432.CCR-06-2427 1:CAS:528:DC%2BD2sXjs12rtLk%3D 17404106 (Pubitemid 46656008)
36. AV Patterson DM Ferry SJ Edmunds YC Gu RS Singleton K Patel, et al. 2007 Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104 Clin Cancer Res 13 3922 3932 10.1158/1078-0432.CCR-07-0478 1:CAS:528:DC%2BD2sXntFymt7w%3D 17606726 (Pubitemid 47037600)
37. JX Duan H Jiao J Kaizerman T Stanton JW Evans L Lan, et al. 2008 Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs J Med Chem 51 2412 2420 10.1021/jm701028q 1:CAS:528: DC%2BD1cXhslWis7s%3D 18257544 (Pubitemid 351628502)
38. JM Pawelek KB Low D Bermudes 2003 Bacteria as tumour-targeting vectors Lancet Oncol 4 548 556 10.1016/S1470-2045(03)01194-X 12965276 (Pubitemid 38351712)
39. MQ Wei A Mengesha D Good J Anné 2008 Bacterial targeted tumour therapy-dawn of a new era Cancer Lett 259 16 27 10.1016/j.canlet.2007.10.034 1:CAS:528:DC%2BD2sXhsVCgtL7E 18063294 (Pubitemid 350245421)
40. DA Mulford DA Scheinberg JG Jurcic 2005 The promise of targeted {alpha}-particle therapy J Nucl Med 46 Suppl 1 199S 204S 15653670